Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
DXCM's Cash-to-Debt is ranked higher than
97% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. DXCM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
DXCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.6  Med: 69.91 Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
DXCM's Equity-to-Asset is ranked higher than
70% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. DXCM: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
DXCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.44  Med: 0.73 Max: 0.88
Current: 0.71
-0.44
0.88
Piotroski F-Score: 4
Altman Z-Score: 33.00
Beneish M-Score: -3.26
WACC vs ROIC
8.09%
-48.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.15
DXCM's Operating Margin % is ranked lower than
60% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. DXCM: -11.15 )
Ranked among companies with meaningful Operating Margin % only.
DXCM' s Operating Margin % Range Over the Past 10 Years
Min: -1008.77  Med: -57.24 Max: -8.29
Current: -11.15
-1008.77
-8.29
Net Margin % -11.44
DXCM's Net Margin % is ranked lower than
58% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. DXCM: -11.44 )
Ranked among companies with meaningful Net Margin % only.
DXCM' s Net Margin % Range Over the Past 10 Years
Min: -991.53  Med: -56.57 Max: -8.64
Current: -11.44
-991.53
-8.64
ROE % -26.36
DXCM's ROE % is ranked lower than
62% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. DXCM: -26.36 )
Ranked among companies with meaningful ROE % only.
DXCM' s ROE % Range Over the Past 10 Years
Min: -259.33  Med: -45.51 Max: -19.97
Current: -26.36
-259.33
-19.97
ROA % -19.42
DXCM's ROA % is ranked lower than
60% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. DXCM: -19.42 )
Ranked among companies with meaningful ROA % only.
DXCM' s ROA % Range Over the Past 10 Years
Min: -117.86  Med: -46.68 Max: -14.59
Current: -19.42
-117.86
-14.59
ROC (Joel Greenblatt) % -49.01
DXCM's ROC (Joel Greenblatt) % is ranked lower than
59% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. DXCM: -49.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DXCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -828.4  Med: -228.52 Max: -47.64
Current: -49.01
-828.4
-47.64
3-Year Revenue Growth Rate 45.00
DXCM's 3-Year Revenue Growth Rate is ranked higher than
95% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. DXCM: 45.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DXCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.1 Max: 103.1
Current: 45
0
103.1
3-Year EBITDA Growth Rate 24.10
DXCM's 3-Year EBITDA Growth Rate is ranked higher than
82% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. DXCM: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DXCM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.8 Max: 24.1
Current: 24.1
0
24.1
3-Year EPS without NRI Growth Rate 22.90
DXCM's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. DXCM: 22.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DXCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40  Med: -15.7 Max: 47.3
Current: 22.9
-40
47.3
GuruFocus has detected 1 Warning Sign with DexCom Inc $DXCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DXCM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DXCM Guru Trades in Q1 2016

John Paulson 41,300 sh (New)
Andreas Halvorsen 486,489 sh (New)
Jim Simons 817,943 sh (+17.87%)
Steven Cohen 257,900 sh (+14.78%)
Ron Baron 1,092,441 sh (+0.18%)
George Soros Sold Out
Mario Gabelli 43,400 sh (-2.25%)
RS Investment Management 734,086 sh (-18.77%)
» More
Q2 2016

DXCM Guru Trades in Q2 2016

John Paulson 123,500 sh (+199.03%)
Steven Cohen 261,000 sh (+1.20%)
Andreas Halvorsen Sold Out
Mario Gabelli 41,900 sh (-3.46%)
Ron Baron 901,677 sh (-17.46%)
RS Investment Management 309,651 sh (-57.82%)
Jim Simons 341,806 sh (-58.21%)
» More
Q3 2016

DXCM Guru Trades in Q3 2016

George Soros 2,576 sh (New)
Jim Simons Sold Out
Mario Gabelli 41,600 sh (-0.72%)
Ron Baron 851,477 sh (-5.57%)
Steven Cohen 183,600 sh (-29.66%)
John Paulson 43,500 sh (-64.78%)
» More
Q4 2016

DXCM Guru Trades in Q4 2016

Jim Simons 137,643 sh (New)
John Paulson 293,200 sh (+574.02%)
George Soros 5,300 sh (+105.75%)
Steven Cohen 192,600 sh (+4.90%)
Steven Cohen 200,000 sh (unchged)
Ron Baron 839,027 sh (-1.46%)
Mario Gabelli 37,300 sh (-10.34%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 3841
Compare:NAS:QGEN, NYSE:PKI, OTCPK:ERFSF, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:BRKR, NAS:VWR, NAS:PRAH, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL, NAS:NEOG, NAS:INCR, NAS:EXAS, NAS:MYGN, NAS:AXDX, NAS:FMI, NAS:VREX, NAS:MEDP » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company's product line includes SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.

Guru Investment Theses on DexCom Inc

Baron Funds Comments on DexCom Inc. - Jan 14, 2016

Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on DexCom Inc. - Aug 19, 2015

DexCom, Inc. (NASDAQ:DXCM) sells a continuous glucose monitoring device for insulin dependent diabetes. DexCom reported very strong results. Revenues grew 55% in the quarter, and the company reiterated guidance for continued exceptional growth. The company launched its “share” system, which allows parents or spouses to receive the users’ blood glucose data from the users’ handheld devices, an important new feature. And they filed for approval of their next generation offering that will transmit data directly to a smartphone, eliminating the need to carry a receiver. Strong new patient starts, more accurate and feature rich products, and an expanding addressable market make for a company that, we believe, can grow rapidly for a considerable time go forward.



From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about DexCom Inc

Weekly CFO Sells Highlights Insiders sell holdings in Fidelity National Financial, DexCom and Facebook
According to GuruFocus Insider Data, the recent CFO sells were: Fidelity National Financial Inc. (NYSE:FNF), DexCom Inc. (NASDAQ:DXCM) and Facebook Inc. (NASDAQ:FB). Read more...

Ratios

vs
industry
vs
history
PB Ratio 24.63
DXCM's PB Ratio is ranked lower than
98% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. DXCM: 24.63 )
Ranked among companies with meaningful PB Ratio only.
DXCM' s PB Ratio Range Over the Past 10 Years
Min: 3.88  Med: 17.93 Max: 194.65
Current: 24.63
3.88
194.65
PS Ratio 12.02
DXCM's PS Ratio is ranked lower than
83% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. DXCM: 12.02 )
Ranked among companies with meaningful PS Ratio only.
DXCM' s PS Ratio Range Over the Past 10 Years
Min: 6.16  Med: 14.65 Max: 25250
Current: 12.02
6.16
25250
Price-to-Free-Cash-Flow 27540.05
DXCM's Price-to-Free-Cash-Flow is ranked lower than
100% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. DXCM: 27540.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DXCM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 289.28  Med: 582.21 Max: 28376.67
Current: 27540.05
289.28
28376.67
Price-to-Operating-Cash-Flow 123.38
DXCM's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. DXCM: 123.38 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DXCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 89.1  Med: 155.32 Max: 1366.67
Current: 123.38
89.1
1366.67
Current Ratio 2.73
DXCM's Current Ratio is ranked higher than
55% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. DXCM: 2.73 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.15 Max: 20.46
Current: 2.73
1.96
20.46
Quick Ratio 2.29
DXCM's Quick Ratio is ranked higher than
54% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. DXCM: 2.29 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s Quick Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.69 Max: 20.46
Current: 2.29
1.82
20.46
Days Inventory 80.27
DXCM's Days Inventory is ranked lower than
52% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. DXCM: 80.27 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s Days Inventory Range Over the Past 10 Years
Min: 35.66  Med: 54.23 Max: 80.27
Current: 80.27
35.66
80.27
Days Sales Outstanding 64.75
DXCM's Days Sales Outstanding is ranked lower than
55% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. DXCM: 64.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.96  Med: 59.63 Max: 71.25
Current: 64.75
16.96
71.25
Days Payable 45.88
DXCM's Days Payable is ranked lower than
58% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. DXCM: 45.88 )
Ranked among companies with meaningful Days Payable only.
DXCM' s Days Payable Range Over the Past 10 Years
Min: 21.26  Med: 31.59 Max: 56.11
Current: 45.88
21.26
56.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
DXCM's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. DXCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137.6  Med: -14.7 Max: -4.6
Current: -5.3
-137.6
-4.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1377.00
DXCM's Price-to-Net-Cash is ranked lower than
100% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.00 vs. DXCM: 1377.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DXCM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.94  Med: 48.54 Max: 1399.33
Current: 1377
5.94
1399.33
Price-to-Net-Current-Asset-Value 43.48
DXCM's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. DXCM: 43.48 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DXCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.6  Med: 19.41 Max: 47.21
Current: 43.48
5.6
47.21
Price-to-Tangible-Book 25.66
DXCM's Price-to-Tangible-Book is ranked lower than
95% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. DXCM: 25.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DXCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.89  Med: 16.23 Max: 35.75
Current: 25.66
4.89
35.75
Price-to-Intrinsic-Value-Projected-FCF 96.07
DXCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
97% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DXCM: 96.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DXCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 69.42  Med: 69.42 Max: 97.63
Current: 96.07
69.42
97.63
Price-to-Median-PS-Value 0.82
DXCM's Price-to-Median-PS-Value is ranked higher than
69% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. DXCM: 0.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DXCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.07 Max: 8.43
Current: 0.82
0.54
8.43
Earnings Yield (Greenblatt) % -0.93
DXCM's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. DXCM: -0.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DXCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.58  Med: 0 Max: 0
Current: -0.93
-1.58
0

More Statistics

Revenue (TTM) (Mil) $573.3
EPS (TTM) $ -0.77
Beta0.74
Short Percentage of Float9.08%
52-Week Range $57.68 - 96.38
Shares Outstanding (Mil)84.82

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 738 985 1,260
EPS ($) -0.56 0.21 1.07
EPS without NRI ($) -0.56 0.21 1.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight Jun 28 2016 
Baron Funds Comments on DexCom Inc. Jan 14 2016 
Investing for Lower Risk Long-Term Growth in a Volatile Asset Class - Baron Funds Winter Newsletter Jan 14 2016 
Top Weekly Insider Sells Highlights Sep 15 2015 
Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks Sep 13 2015 
Panic-Proofing the Small Investor Aug 26 2015 
Baron Funds Comments on DexCom Inc. Aug 19 2015 
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc. Jul 13 2015 

More From Other Websites
8:35 am Dexcom announces that the U.S. Centers for Medicare & Medicaid Services has published an... Mar 24 2017
Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive... Mar 24 2017
DexCom Schedules First Quarter 2017 Earnings Release and Conference Call for May 2, 2017 at 4:30... Mar 23 2017
DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : March 20, 2017 Mar 20 2017
Post Earnings Coverage as DexCom's Q4 Top-line Surged 31%; Outshined Forecasts Mar 16 2017
When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17) Mar 16 2017
DEXCOM INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 13 2017
DexCom Appoints Richard Collins to Board of Directors Mar 13 2017
DEXCOM INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an... Mar 06 2017
DEXCOM INC Financials Mar 04 2017
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues Mar 03 2017
DexCom, Inc. :DXCM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 28 2017
DEXCOM INC Files SEC form 10-K, Annual Report Feb 28 2017
DexCom, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results Feb 28 2017
Q4 2016 DexCom Inc Earnings Release - After Market Close Feb 28 2017
Should You Buy DexCom (DXCM) Ahead of Earnings? Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)